rs898854295
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PP3_StrongPP5_Very_Strong
The NM_003001.5(SDHC):c.377A>G(p.Tyr126Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000483 in 1,613,948 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_003001.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SDHC | NM_003001.5 | c.377A>G | p.Tyr126Cys | missense_variant | Exon 5 of 6 | ENST00000367975.7 | NP_002992.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152082Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.0000506 AC: 74AN: 1461866Hom.: 0 Cov.: 32 AF XY: 0.0000550 AC XY: 40AN XY: 727238
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152082Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74280
ClinVar
Submissions by phenotype
Paragangliomas 3 Pathogenic:2
- -
This missense variant replaces tyrosine with cysteine at codon 126 of the SDHC protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in multiple individuals affected with paraganglioma (PMID: 19245779, 29305721, 32035780, 34558728). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
Hereditary pheochromocytoma-paraganglioma Pathogenic:2
- -
This missense variant replaces tyrosine with cysteine at codon 126 of the SDHC protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in multiple individuals affected with paraganglioma (PMID: 19245779, 29305721, 32035780, 34558728). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -
Gastrointestinal stromal tumor;C1854336:Paragangliomas 3 Pathogenic:1
This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 126 of the SDHC protein (p.Tyr126Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with paragangliomas (internal data). ClinVar contains an entry for this variant (Variation ID: 428933). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt SDHC protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:1
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 34558728, 29305721, 15989954, 36672771, 32035780) -
Gastrointestinal stromal tumor Pathogenic:1
- -
SDHC-related disorder Pathogenic:1
The SDHC c.377A>G variant is predicted to result in the amino acid substitution p.Tyr126Cys. This variant has been reported in five unrelated individuals with head and neck paraganglioma (Lozano Sánchez et al. 2010. Angiologia. 62(6): 214-18. https://doi.org/10.1016/S0003-3170(10)70051-1; Table S1, Verginelli et al. 2018. PubMed ID: 29305721; Supplement, Sen et al. 2020. PubMed ID: 32035780; Tables 3 and S3, Williams et al. 2022. PubMed ID: 34558728). It has also been reported as a likely pathogenic, paternally-inherited secondary finding in a pediatric individual with a neurodevelopmental indication (Table 1, Halfmeyer et al. 2022. PubMed ID: 36672771). This variant is predicted to be protein destabilizing (Williams et al. 2022. PubMed ID: 34558728). This variant has not been reported in gnomAD, indicating this variant is rare. This variant has been reported in ClinVar as likely pathogenic and pathogenic by outside laboratories (https://www.ncbi.nlm.nih.gov/clinvar/variation/428933/). This variant is interpreted as likely pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Y126C variant (also known as c.377A>G), located in coding exon 5 of the SDHC gene, results from an A to G substitution at nucleotide position 377. The tyrosine at codon 126 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been reported in multiple individuals diagnosed with paragangliomas (Ambry internal data; Lozano Sánchez et al. Angiología. 2010;62(6):214-218; Sen I et al. J Vasc Surg, 2020 May;71:1602-1612.e2; Williams ST et al. Clin Endocrinol (Oxf), 2022 Apr;96:499-512). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at